The Clinicopathological Significance of MicroRNA-155 in Breast Cancer: A Meta-Analysis

Table 2

Analysis of miR-155 expression level and different subtype breast cancer.

Comparisons	𝑁	Heterogeneity		Model^a	Effect size
	Studies	𝐼^2 (%)	𝑃(𝑄)		SMD	𝑃(𝑍)
ER+ Versus ER−	7 [16–18, 20, 22, 27, 29]	96	<0.00001	R	−1.2	0.03
PR+ Versus PR−	7 [16–18, 20, 22, 27, 29]	97	<0.00001	R	−1.85	0.01
Her2+ Versus Her2−	4 [20, 22, 25, 29]	50	0.11	F	0.32	0.007
LNM+ Versus LNM−	7 [15–18, 20, 22, 29]	97	<0.00001	R	2.62	0.0001
TNM I/II Versus III/IV	8 [15–18, 22, 26, 28, 29]	96	<0.00001	R	−0.94	0.08
TS 1 Versus 2/3	5 [16, 18, 20, 22, 29]	92	<0.00001	R	−0.58	<0.0001
P53 WT Versus MT	3 [16, 25, 28]	65	0.06	R	−0.79	0.02

𝑁 number of studies, 𝑃(𝑄) 𝑃 value of 𝑄 test for heterogeneity, 𝑃(𝑍) 𝑃 value of 𝑍 test for significant test, LNM lymph node metastasis, TS tumor size, WT wild type, MT mutant type.
^aR: random-effect model; F: fixed-effect model.